Mercury Bio CSO, Dr. Richard Sayre, Presents at the 3rd mRNA-Based Therapeutics Summit
Mercury Bio CSO, Dr. Richard Sayre, Presents at the 3rd mRNA-Based Therapeutics Summit
Dr. Richard Sayre, CSO of Mercury Bio, will present a lecture at the 3rd mRNA-Based Therapeutics Summit entitled: “Enhancing Therapeutic RNA Stability, Delivery & Performance Using Yeast Chimeric Extracellular Vesicles”.
This conference, held July 26-28 in Boston, MA is the world’s largest gathering for mRNA professionals. There are now over 800 mRNA drugs currently in development with the industry accelerating towards clinical success, The mRNA-Based Therapeutics Summit returns for its 3rd year as the industry’s largest opportunity for networking, and sharing data.
In Dr. Sayre’s presentation, he will speak about how Mercury Bio has developed a yeast chimeric extracellular vesicle system for the packaging and targeted delivery of therapeutic RNAs and drugs to patients.
Therapeutic RNAs are directly produced in the yeast and sorted and packaged into extracellular vesicles (EV). Injection of EVs into the bloodstream results in their wide distribution throughout the body. Off-target side effects are substantially reduced by cell- targeting systems that recognize the specific cells where the therapeutics are to be delivered.
Yeast EVs have several advantages over competing drug delivery platforms. Yeast EVs are substantially less costly than lipid nanoparticles or human exosomes. Furthermore, yeast EVs are stable at room temperature unlike lipid nanoparticle delivery platforms which require cold storage (- 80 C). In addition, yeast EVs do not harbor human pathogens, nor do they carry off-target RNAs that could result in unwanted side-effects unlike human exosomes.
Yeast chimeric EVs represent the next generation platform for targeted RNA and drug delivery.
About Mercury Bio
Mercury Bio is a Santa Fe, NM-based biotech research company that has invented a cell-free, targeted, drug delivery platform designed to unlock the potential for RNA therapeutics to treat the roots of diseases—not just their symptoms. This platform technology allows for rapid development and is readily scalable for high-volume needs.
Article by the New Mexico Consortium.